Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Nov;16(5):651–654. doi: 10.1128/aac.16.5.651

Mezlocillin pharmacokinetics in patients with normal and impaired renal functions.

T Bergan, E K Brodwall, E Wiik-Larsen
PMCID: PMC352923  PMID: 526008

Abstract

The pharmacokinetics of intravenous bolus doses of 1.0 g of mezlocillin were studied in 13 persons with normal and reduced renal functions. In renal failure a moderate increase was observed for the terminal serum half-life(t1/2 beta). This changed from a mean of 1.1 h at a glomerular filtration rate of 100 ml/min to 1.6 h at 10 ml/min. The difference was not statistically significant. The excretion of unchanged drug in urine during 24 h was reduced from a mean of 59.4% (range, 52 to 77) in subjects with glomerular filtration rate above 50 ml/min to 10% (range, 7.9 to 12.1) in two patients with glomerular filtration rate of 10 to 20 ml/min. The volume of distribution during the beta-phase, Vd,b, was 14% of the body weight. Much of the antibiotic was metabolized, and this proportion increased upon reduction in renal function.

Full text

PDF
651

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergan T., Brodwall E. K., Oyri A. Renal excretion of gentamycin in chronic pyelonephritis. Acta Med Scand. 1971 Jan-Feb;189(1-2):1–5. doi: 10.1111/j.0954-6820.1971.tb04332.x. [DOI] [PubMed] [Google Scholar]
  2. Bergan T., Oydvin B. Microbiological assay of josamycin. Acta Pathol Microbiol Scand B Microbiol Immunol. 1972;80(1):101–106. doi: 10.1111/j.1699-0463.1972.tb00134.x. [DOI] [PubMed] [Google Scholar]
  3. Bergan T. Pharmacokinetics of mezlocillin in healthy volunteers. Antimicrob Agents Chemother. 1978 Dec;14(6):801–806. doi: 10.1128/aac.14.6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fiegel P., Becker K. Pharmacokinetics of azlocillin in persons with normal and impaired renal functions. Antimicrob Agents Chemother. 1978 Sep;14(3):288–291. doi: 10.1128/aac.14.3.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Issell B. F., Bodey G. P., Weaver S. Clinical pharmacology of mezlocillin. Antimicrob Agents Chemother. 1978 Feb;13(2):180–183. doi: 10.1128/aac.13.2.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lode H., Niestrath U., Koeppe P., Langmaack H. Azlocillin und Mezlocillin: Zwei neue semisynthetische Acylureidopenicilline. Infection. 1977;5(3):163–169. doi: 10.1007/BF01639753. [DOI] [PubMed] [Google Scholar]
  7. Pancoast S. J., Neu H. C. Kinetics of mezlocillin and carbenicillin. Clin Pharmacol Ther. 1978 Jul;24(1):108–116. doi: 10.1002/cpt1978241108. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES